Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy

Cai, Hongzhen; Li, Man; Deng, Ruiyi; Wang, Mopei; Shi, Yanhong

doi:10.1186/s40364-022-00413-0

Cited by 32 publications

(18 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical trials on many other immunosuppressants, such as LAG3, Tim3, TIGIT and OX40, are also being performed. LAG3 and Tim3 are in phase I and II clinical trials, and TIGIT and OX40 are in the early research stage[ 136 ]. Although the toxicity of ICIs may limit their efficacy and clinical application[ 137 ], current evidence indicates that the combined modality of ICIs with other treatments may be more effective and applicable in GC, especially when combined with chemotherapy for advanced GC patients with drug resistance[ 116 , 138 ].…”

Section: Prognostic Factorsmentioning

confidence: 99%

Updates on global epidemiology, risk and prognostic factors of gastric cancer

Yang¹,

Zhao²,

Yu³

et al. 2023

World J Gastroenterol

105

View full text Add to dashboard Cite

Gastric cancer (GC) is defined as the primary epithelial malignancy derived from the stomach, and it is a complicated and heterogeneous disease with multiple risk factors. Despite its overall declining trend of incidence and mortality in various countries over the past few decades, GC remains the fifth most common malignancy and the fourth leading cause of cancer-related death globally. Although the global burden of GC has shown a significant downward trend, it remains severe in certain areas, such as Asia. GC ranks third in incidence and mortality among all cancer types in China, and it accounts for nearly 44.0% and 48.6% of new GC cases and GC-related deaths in the world, respectively. The regional differences in GC incidence and mortality are obvious, and annual new cases and deaths are increasing rapidly in some developing regions. Therefore, early preventive and screening strategies for GC are urgently needed. The clinical efficacies of conventional treatments for GC are limited, and the developing understanding of GC pathogenesis has increased the demand for new therapeutic regimens, including immune checkpoint inhibitors, cell immunotherapy and cancer vaccines. The present review describes the epidemiology of GC worldwide, especially in China, summarizes its risk and prognostic factors, and focuses on novel immunotherapies to develop therapeutic strategies for the management of GC patients.

show abstract

Section: Prognostic Factorsmentioning

confidence: 99%

Updates on global epidemiology, risk and prognostic factors of gastric cancer

Yang¹,

Zhao²,

Yu³

et al. 2023

World J Gastroenterol

105

View full text Add to dashboard Cite

show abstract

“…GC is one of the most common types of cancer around the world (1). Despite of currently treatment options such as surgery, chemotherapy, and radiotherapy, GC mainly reduces the quality of life (55). The overall relative survival rate of GC patients has been improved in the recent years, however it is still poor (56,57).…”

Section: Discussionmentioning

confidence: 99%

Competing endogenous RNA networks reveal long non-coding RNAs as potential prognostic biomarkers in gastric cancer: A systematic review and meta-analysis

Salehi-Mazandarani¹,

Donyavi

Vedaei

et al. 2023

Preprint

View full text Add to dashboard Cite

Aims: Gastric cancer (GC) represents a global health-care challenge. In recent years, a large number of competing endogenous RNA (ceRNA) network studies have elucidated critical long non-coding RNAs (lncRNAs) as potential prognostic biomarkers in GC. Nevertheless, there is no systematic review and meta-analysis regarding them. Here, we propose a systematic review and meta-analysis for lncRNAs as prognostic biomarkers based on the ceRNA network studies in GC. Main methods: The Web of Science, Embase, PubMed, Scopus, ProQuest and Google Scholar databases were searched to collect eligible ceRNA network studies in which lncRNAs were reported as prognostic biomarkers until 27th June 2022. The pooled hazard ratios (HRs) were assessed to evaluate the prognostic effect of the lncRNAs. Prognostic values of highly reported lncRNAs were also examined. Furthermore, sensitivity analysis, and publication bias were evaluated. Key findings: Totally, 35 studies were included in the systematic review among which 13 studies were eligible for meta-analysis. Pooled examination of HRs based on the univariate and multivariate reports revealed that the expression changes of the lncRNAs correlate with overall survival (OS) of GC patients. Two lncRNAs including CCDC144NL-AS1 and LINC01094 were highly reported as potential prognostic biomarkers based on the ceRNA network studies. Prognostic value of these two lncRNAs was furthermore confirmed by meta-analysis. Significance: Our meta-analysis demonstrated potential application of lncRNAs introduced based on the ceRNA network studies as promising prognostic biomarkers in GC. Further functional studies are needed to elucidate the molecular mechanisms underlying these lncRNAs' functions in GC.

show abstract

“… 1 , 2 At present, the treatment options for GC include systemic chemotherapy, surgery, radiotherapy and immunotherapy. 3 Most GC patients are diagnosed as advanced disease. 4 Surgery or chemotherapy alone often yields poor results, and new therapy methods are urgently needed.…”

Section: Introductionmentioning

confidence: 99%

Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022

Chen

Tan

et al. 2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Gastric cancer (GC) is one of the most common malignancies. Immunotherapy becomes an indispensable part of GC. This study conducts bibliometric analysis of immunotherapy for GC to clarify the research status and identify potential new research directions. VOS viewer and CiteSpace visualization software were used to demonstrate collaborations and correlations. A total of 1141 English publications from 2012 to 2022 were included. The number of publications increased year by year. The publications were mainly from China ( n = 579, 50.70%), followed by the United States. Fudan University published the most publications ( n = 48, 4.21%). Frontiers in Oncology and Journal of Clinical Oncology ranked first in cited and co-cited journals, respectively. Kim Kyoung-Mee published the most publications on immunotherapy for GC ( n = 14). The clustering of timeline view and co-cited references show the hotspot transformation on immunotherapy for GC. Initially, the hot topic was “cytokine-induced killer cells” and “myeloid-derived suppressor cells.” In recent years, the focus has turned to “targeted therapy.” “CAR-T” has become the hottest topic, and GC has entered precision therapy phase. Screening patients who can benefit from immunotherapy is key to improving prognosis. The combination of immunotherapy with other treatment options, such as chemotherapy and targeted therapy, is currently the focus of research. Chimeric antigen receptor T cell will be further studied in the future.

show abstract

Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy

Cited by 32 publications

References 100 publications

Updates on global epidemiology, risk and prognostic factors of gastric cancer

Updates on global epidemiology, risk and prognostic factors of gastric cancer

Competing endogenous RNA networks reveal long non-coding RNAs as potential prognostic biomarkers in gastric cancer: A systematic review and meta-analysis

Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022

Contact Info

Product

Resources

About